Patient | Age (years) | Sex | Anatomical site | Diagnosis | Dose of triamcinolone acetonide (mg) | Baseline | Follow up after 2 weeks | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VAS (0–10) | Tenderness (0–3) | GSS (1–4) | PDS (1–4) | VAS* (0–10) | Tenderness* (0–3) | GSS* (1–4) | PDS* (1–4) | ||||||
*p<0.01. | |||||||||||||
GSS, grey scale ultrasonography; PDS, power Doppler ultrasonography; RA, rheumatoid arthritis; PsA, psoriatic arthritis; ReA, reactive arthritis; CPPD, calcium pyrophosphate deposition disease; MTP, metatarsophalangeal joint; MCP, metacarpophalangeal joint; PIP, proximal interphalangeal joint; DIP, distal interphalangeal joint. | |||||||||||||
1 | 30 | F | Wrist | ReA | 20 | 8 | 2 | 2 | 2 | 0 | 0 | 1 | 1 |
2 | 32 | F | Wrist | RA | 20 | 8 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
3 | 81 | M | Wrist | CPPD | 30 | 5 | 2 | 4 | 4 | 3 | 1 | 3 | 3 |
4 | 82 | F | Wrist | RA | 30 | 9 | 3 | 3 | 4 | 1 | 1 | 1 | 2 |
5 | 64 | F | MTP | RA | 10 | 10 | 3 | 2 | 2 | 4 | 2 | 2 | 2 |
6 | 63 | F | MTP | RA | 10 | 10 | 3 | 4 | 4 | 4 | 2 | 3 | 2 |
7 | 30 | F | Wrist | RA | 20 | 7 | 2 | 2 | 3 | 0 | 0 | 1 | 1 |
8 | 54 | F | MCP | PsA | 10 | 7 | 3 | 2 | 2 | 4 | 2 | 1 | 1 |
9 | 55 | F | Wrist | RA | 30 | 10 | 3 | 1 | 1 | 4 | 2 | 1 | 1 |
10 | 82 | F | MCP | RA | 10 | 8 | 3 | 2 | 3 | 0 | 1 | 2 | 1 |
11 | 68 | F | Wrist | RA | 30 | 9 | 3 | 2 | 3 | 4 | 2 | 2 | 2 |
12 | 63 | F | Wrist | RA | 30 | 8 | 3 | 4 | 4 | 3 | 1 | 3 | 2 |
13 | 62 | F | Wrist | RA | 30 | 5 | 2 | 2 | 4 | 3 | 1 | 2 | 2 |
14 | 37 | F | PIP | PsA | 10 | 10 | 3 | 3 | 4 | 1 | 1 | 2 | 1 |
15 | 70 | M | Wrist | CPPD | 30 | 8 | 3 | 2 | 1 | 4 | 2 | 2 | 1 |
16 | 70 | F | Wrist | CPPD | 30 | 8 | 3 | 2 | 3 | 1 | 1 | 1 | 1 |
17 | 30 | M | DIP | PsA | 10 | 8 | 3 | 2 | 4 | 0 | 0 | 1 | 1 |
18 | 31 | M | DIP | PsA | 10 | 6 | 3 | 2 | 2 | 2 | 1 | 1 | 1 |
19 | 30 | M | Wrist | PsA | 20 | 8 | 3 | 3 | 4 | 0 | 0 | 1 | 1 |
20 | 55 | F | Wrist | RA | 20 | 6 | 2 | 3 | 3 | 0 | 1 | 2 | 1 |
Median | 58, 5 | 15F/5M | 8 | 3 | 2 | 3 | 2 | 1 | 2 | 1 |